Combined excision and intralesional bevacizumab for sebaceous carcinoma of the eyelid in an Amur tiger (Panthera tigris altaica)

Michele L. Edelmann, Mary Utter, Lin V. Klein, Kathryn L. Wotman

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

An 18-year-old zoo-kept female Amur tiger presented with an approximately 5mm diameter lateral canthal eyelid mass in the left eye which grossly appeared red and irregular. The mass was completely excised via lateral canthoplasty. Histopathologic evaluation was consistent with a diagnosis of sebaceous cell carcinoma, which is a potentially aggressive cutaneous neoplasm. The sebaceous carcinoma recurred within 3months and slowly increased in size until a second surgical excision was performed 9months following the first surgery. The second surgical excision was combined with intralesional injection of 10mg of the antiangiogenic drug bevacizumab. Histology confirmed the diagnosis. The tiger was euthanized 16months postoperatively for reasons unrelated to, and without recurrence of, the eyelid neoplasm. At postmortem, no gross periocular or metastatic lesions were noted, and histopathology of the lateral canthus provided no evidence of recurrence. Surgical excision combined with intralesional bevacizumab treatment induced life-long resolution of the sebaceous carcinoma. Bevacizumab treatment may be associated with the regression of periocular angiogenic proliferative conditions, including neoplasia, by inhibiting angiogenesis.

Original languageEnglish (US)
Pages (from-to)219-224
Number of pages6
JournalVeterinary Ophthalmology
Volume16
Issue number3
DOIs
StatePublished - May 1 2013
Externally publishedYes

Fingerprint

Panthera tigris altaica
Tigers
eyelids
excision
Panthera tigris
Eyelids
carcinoma
Carcinoma
Eyelid Neoplasms
neoplasms
Intralesional Injections
Recurrence
Lacrimal Apparatus
Skin Neoplasms
angiogenesis
zoos
lesions (animal)
histopathology
histology
Histology

Keywords

  • Amur tiger
  • Antiangiogenic
  • Bevacizumab
  • Eyelid
  • Sebaceous carcinoma
  • Vascular endothelial growth factor

ASJC Scopus subject areas

  • veterinary(all)

Cite this

Combined excision and intralesional bevacizumab for sebaceous carcinoma of the eyelid in an Amur tiger (Panthera tigris altaica). / Edelmann, Michele L.; Utter, Mary; Klein, Lin V.; Wotman, Kathryn L.

In: Veterinary Ophthalmology, Vol. 16, No. 3, 01.05.2013, p. 219-224.

Research output: Contribution to journalArticle

@article{cfe222151ce649c2a89feac059da1f20,
title = "Combined excision and intralesional bevacizumab for sebaceous carcinoma of the eyelid in an Amur tiger (Panthera tigris altaica)",
abstract = "An 18-year-old zoo-kept female Amur tiger presented with an approximately 5mm diameter lateral canthal eyelid mass in the left eye which grossly appeared red and irregular. The mass was completely excised via lateral canthoplasty. Histopathologic evaluation was consistent with a diagnosis of sebaceous cell carcinoma, which is a potentially aggressive cutaneous neoplasm. The sebaceous carcinoma recurred within 3months and slowly increased in size until a second surgical excision was performed 9months following the first surgery. The second surgical excision was combined with intralesional injection of 10mg of the antiangiogenic drug bevacizumab. Histology confirmed the diagnosis. The tiger was euthanized 16months postoperatively for reasons unrelated to, and without recurrence of, the eyelid neoplasm. At postmortem, no gross periocular or metastatic lesions were noted, and histopathology of the lateral canthus provided no evidence of recurrence. Surgical excision combined with intralesional bevacizumab treatment induced life-long resolution of the sebaceous carcinoma. Bevacizumab treatment may be associated with the regression of periocular angiogenic proliferative conditions, including neoplasia, by inhibiting angiogenesis.",
keywords = "Amur tiger, Antiangiogenic, Bevacizumab, Eyelid, Sebaceous carcinoma, Vascular endothelial growth factor",
author = "Edelmann, {Michele L.} and Mary Utter and Klein, {Lin V.} and Wotman, {Kathryn L.}",
year = "2013",
month = "5",
day = "1",
doi = "10.1111/j.1463-5224.2012.01051.x",
language = "English (US)",
volume = "16",
pages = "219--224",
journal = "Veterinary Ophthalmology",
issn = "1463-5216",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Combined excision and intralesional bevacizumab for sebaceous carcinoma of the eyelid in an Amur tiger (Panthera tigris altaica)

AU - Edelmann, Michele L.

AU - Utter, Mary

AU - Klein, Lin V.

AU - Wotman, Kathryn L.

PY - 2013/5/1

Y1 - 2013/5/1

N2 - An 18-year-old zoo-kept female Amur tiger presented with an approximately 5mm diameter lateral canthal eyelid mass in the left eye which grossly appeared red and irregular. The mass was completely excised via lateral canthoplasty. Histopathologic evaluation was consistent with a diagnosis of sebaceous cell carcinoma, which is a potentially aggressive cutaneous neoplasm. The sebaceous carcinoma recurred within 3months and slowly increased in size until a second surgical excision was performed 9months following the first surgery. The second surgical excision was combined with intralesional injection of 10mg of the antiangiogenic drug bevacizumab. Histology confirmed the diagnosis. The tiger was euthanized 16months postoperatively for reasons unrelated to, and without recurrence of, the eyelid neoplasm. At postmortem, no gross periocular or metastatic lesions were noted, and histopathology of the lateral canthus provided no evidence of recurrence. Surgical excision combined with intralesional bevacizumab treatment induced life-long resolution of the sebaceous carcinoma. Bevacizumab treatment may be associated with the regression of periocular angiogenic proliferative conditions, including neoplasia, by inhibiting angiogenesis.

AB - An 18-year-old zoo-kept female Amur tiger presented with an approximately 5mm diameter lateral canthal eyelid mass in the left eye which grossly appeared red and irregular. The mass was completely excised via lateral canthoplasty. Histopathologic evaluation was consistent with a diagnosis of sebaceous cell carcinoma, which is a potentially aggressive cutaneous neoplasm. The sebaceous carcinoma recurred within 3months and slowly increased in size until a second surgical excision was performed 9months following the first surgery. The second surgical excision was combined with intralesional injection of 10mg of the antiangiogenic drug bevacizumab. Histology confirmed the diagnosis. The tiger was euthanized 16months postoperatively for reasons unrelated to, and without recurrence of, the eyelid neoplasm. At postmortem, no gross periocular or metastatic lesions were noted, and histopathology of the lateral canthus provided no evidence of recurrence. Surgical excision combined with intralesional bevacizumab treatment induced life-long resolution of the sebaceous carcinoma. Bevacizumab treatment may be associated with the regression of periocular angiogenic proliferative conditions, including neoplasia, by inhibiting angiogenesis.

KW - Amur tiger

KW - Antiangiogenic

KW - Bevacizumab

KW - Eyelid

KW - Sebaceous carcinoma

KW - Vascular endothelial growth factor

UR - http://www.scopus.com/inward/record.url?scp=84876719163&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876719163&partnerID=8YFLogxK

U2 - 10.1111/j.1463-5224.2012.01051.x

DO - 10.1111/j.1463-5224.2012.01051.x

M3 - Article

C2 - 22857265

AN - SCOPUS:84876719163

VL - 16

SP - 219

EP - 224

JO - Veterinary Ophthalmology

JF - Veterinary Ophthalmology

SN - 1463-5216

IS - 3

ER -